"10.1371_journal.pone.0018048","plos one","2011-03-28T00:00:00Z","Lorenz Bott-Fl체gel; Alexandra Bernshausen; Heike Schneider; Peter Luppa; Katja Zimmermann; Barbara Albrecht-K체pper; Raimund Kast; Karl-Ludwig Laugwitz; Heimo Ehmke; Andreas Knorr; Melchior Seyfarth","1. Medizinische Klinik, Klinikum rechts der Isar and Deutsches Herzzentrum M체nchen, Technische Universit채t, M체nchen, Germany; Institut f체r Klinische Chemie und Pathobiochemie, Klinikum rechts der Isar, Technische Universit채t, M체nchen, Germany; Bayer Schering Pharma AG, Global Drug Discovery, Wuppertal, Germany; Institut f체r Vegetative Physiologie und Pathophysiologie, Universit채tsklinikum Hamburg-Eppendorf, Hamburg, Germany; Medizinische Klinik 3, HELIOS Klinikum Wuppertal and Lehrstuhl f체r Kardiologie, Universit채t Witten/Herdecke, Witten, Germany","Conceived and designed the experiments: LBF KCZ KLL HE AK MS. Performed the experiments: LBF AB HS KCZ BAK RK. Analyzed the data: LBF HS PL KCZ BAK RK KLL HE AK MS. Contributed reagents/materials/analysis tools: HS KCZ AK. Wrote the paper: LBF HE MS.","L. Bott-Fl체gel received travel fees from Bayer Schering Pharma GmbH. H. Ehmke serves as consultant to Bayer Schering Pharma GmbH. K. Zimmermann, A. Knorr, B. Albrecht-K체pper, and R. Kast are employees of Bayer Schering Pharma GmbH. Bayer Schering Pharma provided funding for the in vivo studies and took part in the design, data aquisition and analysis of the in vivo experiments. The principal investigators (L. Bott-Fl체gel, H. Ehmke, and Melchior Seyfarth) had access to the raw data, and Bayer Schering had no role in the interpretation of the data and decision to publish. The authors declare that funding by Bayer Schering Pharma does not influence their adherence to the PLoS ONE policies on sharing data and materials.","2011","03","Lorenz Bott-Fl체gel","LBF",11,TRUE,6,6,10,3,TRUE,TRUE,FALSE,0,NA,FALSE
